CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
Main Article Content
Keywords
adults T cell acute lymphoblastic leukemia, CAR-T Cells, T-cell lymphoblastic lymphoma
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs and multiple myeloma.
These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies. However, the success of CAR-T cell therapies in T-cell neoplasms was considerably more limited to the existence of some limiting factors, such as the sharing of mutual antigens between normal T-cells and CAR-T cells, and malignant cells, determining fratricide events and severe T-cell aplasia; contamination of CAR-T cells used for CAR transduction with contaminating malignant T-cells. Allogeneic CAR-T products can avoid tumor contamination but raise other problems related to immunological incompatibility.
In spite of these limitations, there has been significant progress in CD7- and CD5-targeted CAR-T cell therapy of T-cell malignancies in the last few years.
Downloads
Abstract 1296
PDF Downloads 1444
HTML Downloads 59
References
1. Van der Zwet JCG, Cordo V, Cante-Barrett K, Meijerink JPP. Multiomic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients. Adv Biol Reg 2019; 74: 100647.
2. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 2017; 49: 1211-1218.
3. Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y. Recurrent SPI1 (PU1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 2017; 49: 1274-1281.
4. DuVall AS, Sheade J, Anderson D, Yates SJ, Stock W. Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatment in being answered. JCO Oncol Pract 2022; 18: 479-487.
5. Stuver R, Moskowitz AJ. Therapeutic advances in relapsed and refractory peripheral T-cell lymphoma. Cancer 2023, 15: 589.
6. Liu J, Zhang Y, Guo R, Zhao Y, Sun R, Guo S, Lu W, Zhao M. Targeted CD7 CAR T-cells for treatment of T-lymphocte leukemia and lymphoma and acute myeloid leukemia: recent advances. Fron Immunol 2023; 14: 1170968.
7. Frankel AE, Laver JH, Willigham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin a chain immunotoxin. Leukemia Lymphoma 1997; 26: 287-298.
8. Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 2017; 130: 285-296.
9. Depil S, Duchhateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020; 19: 185-199.
10. Xie L, Gu R, Yang X, Qiu S, Xu Y, Mou J, Wang Y, Xing H, Tang K, Tian Z, et al. Universal anti-CD7 antigen on T/CAR-T cells. Blood 2022; 140 (suppl.1): 4535.
11. Hu Y, Zhou Y, Zhang M, Zhao H, Wiei G, Ge W, Cui Q, Mu Q, Chen G, Han L, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res 2022; 32: 995-1007.
12. Zhang X, Zhou Y, Yang J, Li J, Qiu L, Ge W, Pei B, Chen J, Han L, Ren J, Lu P. A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood 2022; 140 (suppl.1): 4566-4567.
13. Leedom T, Hamil AS, Pouyanfard S, Govero J, Langland R, Ballard A, Schwarzkopf L, Martens A, Espenchied A, Vinay P, et al. Characterization of WU-CART-007, an allogeneic CD7-targeted CAR-T cell therapy for T-cell malignancies. Blood 2021; 138 (suppl. 1): 703.
14. Ghobadi A, Aldoss I, Maudfe S, Wayne AS, Bhoywani D, Bajhel A, Dholaria B, Faramand R, Mattison R, Rettig M, et al. Phase 1-2 dose-escalation study of anti-CD7 allogeneic CAR-T cell in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). HemaSphere 2023; 7 (s3): P356.
15. Li S, Wang X, Yuan Z, Liu L, Luo L, Li Y, Wu K, Liu J, Yang C, Li Z, et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin Cancer Res 2021; 27: 1242-1246.
16. Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, Gao L, Li Y, Lou L, Li G, et al. CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia 2023; in press.
17. Dioiorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J, Coholan L, Edwards A, Fuller T, Gonzalez C, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 2022; 140: 619-629.
18. Chiesa R, Georgiadis C, Syed F, Zhou H, Etuk A, Gkazi SA, Preece R, Ottaviano G, Braybrook Y, Chu J, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med 2023; 389: 899-910.
19. Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith N, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv 2017; 1: 1248-1260.
20. Kamiya T, WONG D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv 2028; 2: 517-528.
21. Wong XFA,Ng J, Zheng S, Ismail R, Qian H, Campana D. Development of an off-the-Sh elf chimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblastic leukemia (T-ALL) without gene editing. Blood 2022; 140 (suppl.1): 2358-2359.
22. M, Chen D Zhang, Fu X, Meng H, Nan F, Sun Z, Yu H, Zhang L, Li L, Li X, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res 2022; 28: 2830-2843.
23. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol 2021; 39: 3340-3351.
24. Tan Y, Pan J, Deng B, Ling Z, Weiliang S, Tian Z, Cao M, Xu J, Duan J, Wang Z, et al. Efficacy and safety of donor-derived CD7 CART cells for r/r T-cell acute lymphoblastic leukemia/lymphoma: interim analysis from a phase 2 trial. Blood 2022; 140 (suppl. 1): 4602-4603.
25. Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, et al. Long-term follow-up of donor-derived CD7 CAR-T cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2023; 16: 34.
26. Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, Patil SL, Khanlari M, Inaba H, Klco JM, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood 2022; 140: 2684-2694.
27. Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, Wang L, Wang D, Jin D, Li J, Huang X. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood 2022; 140: 321-334.
28. -Zhang X, Yang J, Li J, Qiu L, Zhang J, Lu Y, Zhao YL, Jin D, Li J, Lu P. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023 Dec;98(12):1898-1908. doi: 10.1002/ajh.27094. Epub 2023 Sep 23. Erratum in: Am J Hematol. 2024 Jan 15;
29. Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, Kang Y, Xu J, Wu Z, Wang X, et al. Allogeneic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J 2023; 13: 61
30. Jiang J, Chen J, Liao C, Duan Y, Wang Y, Shang K, Huang Y, Tang Y, Gao X, Gu Y, Sun J. Inserting EF1-drivem CD7-sepcific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia 2023; 37: 1660-1670.
31. Yo J, Jia Y, Tuhin IJ, Tan J, Monty MA, Xu N, Kang L, Li M, Lou X, Zhou M, et al. Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Mol Ther Oncolyt 2022; 24: 719-728.
32. Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Metha B, et al. Feasibility and preclinical efficacy of CD7-medaited CD7 CAR T cells for T cell malignancies. Mol Ther 2023; 31: 24-34.
33. Dai Z, Mu W, Zhao Y, Jia X, Liu J, Wei Q, Tan T, Zhou J. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther 2021; 29: 2707-2714.
34. Ho LY, Yu SR, Jeong JH, Lee HJ, Cho HJ, Kim HC. Mitigating the CD5 CAR-CD5 interaction enhances the functionality of CD5 CAR-t cells by alleviating the T-cell fratricide. Cancer Res 2023; 83 (suppl. 7): 4086.
35. Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, Jia X, Liu J, Wei Q, Wang M, et al. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transd Targeted Therapy 2022; 7: 85.
36. Hill LC, Rouce RH, Smith TS, Yang L, Srinivasan M, Zhang H, Perconti S, Mehta B, Dekhova O, Randall J, et al. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies. Blood 2019; 134 (suppl. 1): 199.
37. Rouce RH, Hill LC, Smith TS, Yang L, Boriskie B, Srinivasan M, Zhang H, Perconti S, Mehta B, Dakhova O, et al. Early signals of anti-tumor efficacy and safety with autologous CD5.CAR T-cells in patients with refractory/relapsed T-cell lymphoma. Blood 2021; 138 (suppl.1): 654.
38. Pan J, Tan Y, Shan L, Deng B, Ling Z, Song W, Feng X, Hu G. Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia. J Clin Oncol 2022; 40: 7028.
39. Patel RP, Ghilardi G, Porazzi P, Yang S, Qian D, Pajarillo R, Wang M, Zhang Y, Schuster SJ, Barta SK, et al. Clinical development of Senza 5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5+ nodal T-cell lymphoma. Blood 2022; 140 (suppl. 1): 1604-1605.
40. Chun I, Kim KH, Chiang YH, Xie W, Lee Y, Pajarillo R, Rotolo A, Shestova O, Hong SJ, Abdel-Mohsen M, et al. CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chiemeric antigen receptor T cells. Blood 2020; 136 (suppl.1): 51-52.
41. Scarfò I, Ormhoj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 2018; 132: 1495-1506.
42. Frigault MJ, Chen YB, Gallagher K, Horick NK, El-Jawahri A, Scarfò I, Wehrli M, Huang L, Casey K, Cook D, et al. Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies. Blood 2021; 138 (suppl.1): 653.
43. Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, AI Wz. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Adv 2022; 6: 2290-2299.
44. Iyer SP, Sica A, Ho J, Hu B, Zain J, Prica A, Weng WK, Kim YH, Kodadoust MS, Palomba ML, et al. The cobalt-lym study of CTX 130: a phase 1 dose-escalation study of CD70-targeted allogeneic CRSPS-CAS9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies. HemaSphere 2022; 6: 53.
45. Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, et al. Targeting the T cell receptor -chain constant region for immunotherapy of T cell malignancies. Nat Med 2017; 23: 1416-1423.
46. Cwynarski K, Iacoboni G, Thoulouili E, Menne T, Irvine D, Balasubramaniam N, Wood L, Stephens C, Shang J, Xue E, et al. First in human study of AUTO4, a TRBC1 targeting CAR T cell therapy in relapsed/refractory TRBC1-positive peripheral T cell lymphoma. Blood 2022; 140 (suppl. 1): 10316-10317.
47. Ureshino H, Kamachi K, Kimura S. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma Leuk 2019; 19: 326-331.
48. Moore DC, Elmes JB, Shibu PA. Mogamulizumab: an anti-CC chemokine receptor 4 antibody for T-cell lymphomas. Ann Pharmacother 2020; 54: 371-379.
49. Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera PY. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol 2017; 92: 892-901.
50. Watanabe K, Goemz AM, Kuramitsu S, Siurala M, Du T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, et al. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood Adv 2023; 7: 3416-3430.
51. Maciocia PM, Wawrzienecka PA, Maciocia nC. Burley A, Karpanasamy T, Devereaux S, Heokx M, O’Connor D, Leon T, Rapoz-D’Silva T, et al. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood 2022; 140: 25-37.
52. Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, O’Neal J, Ritchey JK, Rettig MP, Gao F, Rettig G, et al. An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies. Leukemia 2023; 37: 2448-2456.
53. Gilsovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv 2023; 22: 4418-4430.
2. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 2017; 49: 1211-1218.
3. Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y. Recurrent SPI1 (PU1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 2017; 49: 1274-1281.
4. DuVall AS, Sheade J, Anderson D, Yates SJ, Stock W. Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatment in being answered. JCO Oncol Pract 2022; 18: 479-487.
5. Stuver R, Moskowitz AJ. Therapeutic advances in relapsed and refractory peripheral T-cell lymphoma. Cancer 2023, 15: 589.
6. Liu J, Zhang Y, Guo R, Zhao Y, Sun R, Guo S, Lu W, Zhao M. Targeted CD7 CAR T-cells for treatment of T-lymphocte leukemia and lymphoma and acute myeloid leukemia: recent advances. Fron Immunol 2023; 14: 1170968.
7. Frankel AE, Laver JH, Willigham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin a chain immunotoxin. Leukemia Lymphoma 1997; 26: 287-298.
8. Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 2017; 130: 285-296.
9. Depil S, Duchhateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020; 19: 185-199.
10. Xie L, Gu R, Yang X, Qiu S, Xu Y, Mou J, Wang Y, Xing H, Tang K, Tian Z, et al. Universal anti-CD7 antigen on T/CAR-T cells. Blood 2022; 140 (suppl.1): 4535.
11. Hu Y, Zhou Y, Zhang M, Zhao H, Wiei G, Ge W, Cui Q, Mu Q, Chen G, Han L, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res 2022; 32: 995-1007.
12. Zhang X, Zhou Y, Yang J, Li J, Qiu L, Ge W, Pei B, Chen J, Han L, Ren J, Lu P. A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood 2022; 140 (suppl.1): 4566-4567.
13. Leedom T, Hamil AS, Pouyanfard S, Govero J, Langland R, Ballard A, Schwarzkopf L, Martens A, Espenchied A, Vinay P, et al. Characterization of WU-CART-007, an allogeneic CD7-targeted CAR-T cell therapy for T-cell malignancies. Blood 2021; 138 (suppl. 1): 703.
14. Ghobadi A, Aldoss I, Maudfe S, Wayne AS, Bhoywani D, Bajhel A, Dholaria B, Faramand R, Mattison R, Rettig M, et al. Phase 1-2 dose-escalation study of anti-CD7 allogeneic CAR-T cell in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). HemaSphere 2023; 7 (s3): P356.
15. Li S, Wang X, Yuan Z, Liu L, Luo L, Li Y, Wu K, Liu J, Yang C, Li Z, et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin Cancer Res 2021; 27: 1242-1246.
16. Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, Gao L, Li Y, Lou L, Li G, et al. CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia 2023; in press.
17. Dioiorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J, Coholan L, Edwards A, Fuller T, Gonzalez C, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 2022; 140: 619-629.
18. Chiesa R, Georgiadis C, Syed F, Zhou H, Etuk A, Gkazi SA, Preece R, Ottaviano G, Braybrook Y, Chu J, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med 2023; 389: 899-910.
19. Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith N, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv 2017; 1: 1248-1260.
20. Kamiya T, WONG D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv 2028; 2: 517-528.
21. Wong XFA,Ng J, Zheng S, Ismail R, Qian H, Campana D. Development of an off-the-Sh elf chimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblastic leukemia (T-ALL) without gene editing. Blood 2022; 140 (suppl.1): 2358-2359.
22. M, Chen D Zhang, Fu X, Meng H, Nan F, Sun Z, Yu H, Zhang L, Li L, Li X, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res 2022; 28: 2830-2843.
23. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol 2021; 39: 3340-3351.
24. Tan Y, Pan J, Deng B, Ling Z, Weiliang S, Tian Z, Cao M, Xu J, Duan J, Wang Z, et al. Efficacy and safety of donor-derived CD7 CART cells for r/r T-cell acute lymphoblastic leukemia/lymphoma: interim analysis from a phase 2 trial. Blood 2022; 140 (suppl. 1): 4602-4603.
25. Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, et al. Long-term follow-up of donor-derived CD7 CAR-T cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 2023; 16: 34.
26. Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, Patil SL, Khanlari M, Inaba H, Klco JM, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood 2022; 140: 2684-2694.
27. Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, Wang L, Wang D, Jin D, Li J, Huang X. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood 2022; 140: 321-334.
28. -Zhang X, Yang J, Li J, Qiu L, Zhang J, Lu Y, Zhao YL, Jin D, Li J, Lu P. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023 Dec;98(12):1898-1908. doi: 10.1002/ajh.27094. Epub 2023 Sep 23. Erratum in: Am J Hematol. 2024 Jan 15;
29. Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, Kang Y, Xu J, Wu Z, Wang X, et al. Allogeneic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J 2023; 13: 61
30. Jiang J, Chen J, Liao C, Duan Y, Wang Y, Shang K, Huang Y, Tang Y, Gao X, Gu Y, Sun J. Inserting EF1-drivem CD7-sepcific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia 2023; 37: 1660-1670.
31. Yo J, Jia Y, Tuhin IJ, Tan J, Monty MA, Xu N, Kang L, Li M, Lou X, Zhou M, et al. Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Mol Ther Oncolyt 2022; 24: 719-728.
32. Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Metha B, et al. Feasibility and preclinical efficacy of CD7-medaited CD7 CAR T cells for T cell malignancies. Mol Ther 2023; 31: 24-34.
33. Dai Z, Mu W, Zhao Y, Jia X, Liu J, Wei Q, Tan T, Zhou J. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther 2021; 29: 2707-2714.
34. Ho LY, Yu SR, Jeong JH, Lee HJ, Cho HJ, Kim HC. Mitigating the CD5 CAR-CD5 interaction enhances the functionality of CD5 CAR-t cells by alleviating the T-cell fratricide. Cancer Res 2023; 83 (suppl. 7): 4086.
35. Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, Jia X, Liu J, Wei Q, Wang M, et al. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transd Targeted Therapy 2022; 7: 85.
36. Hill LC, Rouce RH, Smith TS, Yang L, Srinivasan M, Zhang H, Perconti S, Mehta B, Dekhova O, Randall J, et al. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies. Blood 2019; 134 (suppl. 1): 199.
37. Rouce RH, Hill LC, Smith TS, Yang L, Boriskie B, Srinivasan M, Zhang H, Perconti S, Mehta B, Dakhova O, et al. Early signals of anti-tumor efficacy and safety with autologous CD5.CAR T-cells in patients with refractory/relapsed T-cell lymphoma. Blood 2021; 138 (suppl.1): 654.
38. Pan J, Tan Y, Shan L, Deng B, Ling Z, Song W, Feng X, Hu G. Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia. J Clin Oncol 2022; 40: 7028.
39. Patel RP, Ghilardi G, Porazzi P, Yang S, Qian D, Pajarillo R, Wang M, Zhang Y, Schuster SJ, Barta SK, et al. Clinical development of Senza 5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5+ nodal T-cell lymphoma. Blood 2022; 140 (suppl. 1): 1604-1605.
40. Chun I, Kim KH, Chiang YH, Xie W, Lee Y, Pajarillo R, Rotolo A, Shestova O, Hong SJ, Abdel-Mohsen M, et al. CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chiemeric antigen receptor T cells. Blood 2020; 136 (suppl.1): 51-52.
41. Scarfò I, Ormhoj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 2018; 132: 1495-1506.
42. Frigault MJ, Chen YB, Gallagher K, Horick NK, El-Jawahri A, Scarfò I, Wehrli M, Huang L, Casey K, Cook D, et al. Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies. Blood 2021; 138 (suppl.1): 653.
43. Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, AI Wz. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Adv 2022; 6: 2290-2299.
44. Iyer SP, Sica A, Ho J, Hu B, Zain J, Prica A, Weng WK, Kim YH, Kodadoust MS, Palomba ML, et al. The cobalt-lym study of CTX 130: a phase 1 dose-escalation study of CD70-targeted allogeneic CRSPS-CAS9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies. HemaSphere 2022; 6: 53.
45. Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, et al. Targeting the T cell receptor -chain constant region for immunotherapy of T cell malignancies. Nat Med 2017; 23: 1416-1423.
46. Cwynarski K, Iacoboni G, Thoulouili E, Menne T, Irvine D, Balasubramaniam N, Wood L, Stephens C, Shang J, Xue E, et al. First in human study of AUTO4, a TRBC1 targeting CAR T cell therapy in relapsed/refractory TRBC1-positive peripheral T cell lymphoma. Blood 2022; 140 (suppl. 1): 10316-10317.
47. Ureshino H, Kamachi K, Kimura S. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma Leuk 2019; 19: 326-331.
48. Moore DC, Elmes JB, Shibu PA. Mogamulizumab: an anti-CC chemokine receptor 4 antibody for T-cell lymphomas. Ann Pharmacother 2020; 54: 371-379.
49. Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera PY. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol 2017; 92: 892-901.
50. Watanabe K, Goemz AM, Kuramitsu S, Siurala M, Du T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, et al. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood Adv 2023; 7: 3416-3430.
51. Maciocia PM, Wawrzienecka PA, Maciocia nC. Burley A, Karpanasamy T, Devereaux S, Heokx M, O’Connor D, Leon T, Rapoz-D’Silva T, et al. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood 2022; 140: 25-37.
52. Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, O’Neal J, Ritchey JK, Rettig MP, Gao F, Rettig G, et al. An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies. Leukemia 2023; 37: 2448-2456.
53. Gilsovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv 2023; 22: 4418-4430.
Article Sidebar
Published
Feb 29, 2024
Article Details
How to Cite
Testa, U. (2024) “CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES: CAR-T CELL FOR T-CELL MALIGNANCIES”, Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024031. doi: 10.4084/MJHID.2024.031.
Section
Review Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.